Neuraxis (NRXS) Net Income towards Common Stockholders (2022 - 2025)
Neuraxis (NRXS) posted Net Income towards Common Stockholders of -$1.9 million for Q4 2025, up 18.0% sequentially from -$2.3 million in Q3 2025, and down 17.91% YoY from -$2.3 million in Q4 2024.
Neuraxis (NRXS) Net Income towards Common Stockholders (2022 - 2025) Analysis & Trends
Neuraxis has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$1.9 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 17.91% year-over-year to -$1.9 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (up 30.61% YoY) and the FY2025 annual result came in at -$8.6 million, down 1.92% from the prior year.
- Net Income towards Common Stockholders rose to -$1.9 million in Q4 2025 per NRXS's latest filing, from -$2.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$206423.0 in Q4 2022 and troughed at -$5.3 million in Q4 2023.
- A 4-year average of -$2.3 million and a median of -$2.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 2473.99% in 2023, then surged 69.62% in 2024.
- Over 4 years, Net Income towards Common Stockholders stood at -$206423.0 in 2022, then sank by 2473.99% to -$5.3 million in 2023, then soared by 69.62% to -$1.6 million in 2024, then dropped by 17.91% to -$1.9 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.9 million, -$2.3 million, and -$1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -2.32 Mn |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -2.49 Mn |
| Dec 31, 2024 | -1.61 Mn |
| Sep 30, 2024 | -1.80 Mn |
| Jun 30, 2024 | -2.92 Mn |
| Mar 31, 2024 | -2.12 Mn |
| Dec 31, 2023 | -5.31 Mn |
| Sep 30, 2023 | -4.90 Mn |
| Jun 30, 2023 | -2.43 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Dec 31, 2022 | -206,423.00 |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -1.71 Mn |